Melanoma Research Victoria

Source: Healio, April 2019 HILADELPHIA — A choroidal melanoma therapy has been shown to reduce tumor thickness and preserve best corrected visual acuity in patients participating in a phase 1b/2 study, according to a speaker here. AU-011 (Aura Biosciences) has been administered to 30 patients with choroidal melanoma, demonstrating 87% tumor control in subjects with a single […]

Read the full story

Source: Fierce Biotech, April 2019 AstraZeneca has teamed up with Seres Therapeutics to explore whether microbiome therapeutics can increase the efficacy of cancer immunotherapies. The deal will see AstraZeneca pay $20 million to collaborate with Seres and test SER-401 in combination with its oncology assets. Seres firmed up its interest in using microbiome therapeutics in immuno-oncology when […]

Read the full story

Source: The ASCO Post, April 2019 In the phase IIIb/IV CheckMate 511 study reported by Lebbé et al in the Journal of Clinical Oncology, a regimen of nivolumab at 3 mg/kg plus ipilimumab at 1 mg/kg (NIVO3+IPI1) was found to significantly reduce the incidence of treatment-related grade 3 to 5 adverse events compared with nivolumab at 1 […]

Read the full story

Source: Oncology Nurse Advisor, April 2019 Prevalence of anorectal mucosal melanoma (ARMM) has increased. In addition, use of immunotherapy to treat the disease has also increased, over an 11-year period, results from a retrospective study has shown. This study was published in the World Journal of Surgery. Mucosal melanomas in general, and ARMM in particular, represent […]

Read the full story